Premium
Establishment of a HPLC method for preclinical pharmacokinetic study of the novel anti‐Parkinson's disease candidate drug FLZ in rats
Author(s) -
Li Libo,
Zhang Jinlan,
Wang Yuxiang,
Wei Huailing,
Liu Gengtao
Publication year - 2008
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.1004
Subject(s) - pharmacokinetics , chemistry , chromatography , high performance liquid chromatography , calibration curve , extraction (chemistry) , relative standard deviation , detection limit , pharmacology , medicine
An HPLC method was established and validated for the determination of compound FLZ, a synthetic novel anti‐Parkinson's disease candidate drug, in rat plasma. FLZ and the internal standard bicyclol were extracted from plasma by solid‐phase extraction method and analyzed on a Restek C 18 column (4.6 × 250 mm, 5 µm) with a mobile phase consisting of methanol and water (60:40, v/v) at a flow rate of 1.0 mL/min. The detection wavelength was set at 320 nm. The calibration curve was linear within the concentration range from 25 to 500 ng/mL ( r 2 > 0.999), the limit of quantitation was 25 ng/mL and the average recovery was 92.0% with the RSD less than 5.9%. The relative standard deviation for intra‐ and inter‐day precision was less than 3.8 and 6.9%, respectively. The established HPLC method was validated to be a simple, rapid and reliable procedure and applied to study the preclinical pharmacokinetics of FLZ in rat plasma, and it was the first time that the pharmacokinetics of FLZ had been investigated. Copyright © 2008 John Wiley & Sons, Ltd.